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Abstract  
Four novel gold(III) complexes of general formulae [AuCl2{(S,S)-R2eddl}]PF6 (R2eddl = 
O,O’-dialkyl-(S,S)-ethylenediamine-N,N’-di-2-(4-methyl)pentanoate, R = n-Pr, n-Bu, n-Pe, i-
Bu; 1–4, respectively), were synthesized and characterized by elemental analysis, UV/Vis, 
IR, and NMR spectroscopy, as well as high resolution mass spectrometry. Density functional 
theory calculations pointed out that (R,R)-N,N’-configuration diastereoisomers were 
energetically the most favorable. Duo to high cytotoxic activity complex 3 was chosen for 
stability study in DMSO, no decomposition occurs within 24h, and for the reaction with 
                                                          
*
 Corresponding author. Fax: +49 345 5582 1309; Phone: +49 345 5582 1370 
  E-mail address: Goran.Kaluderovic@ipb-halle.de (G. N. Kaluđerović); 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
2 
 
ascorbic acid in which was reduced immediately. Additionally, 3 interacts with bovine serum 
albumin (BSA) as proven by UV/Vis spectroscopy. In vitro antitumor activity was 
determined against human cervix adenocarcinoma (HeLa), human myelogenous leukemia 
(K562), and human melanoma (Fem-x) cancer cell lines, as well as against non-cancerous 
human embryonic lung fibroblast cells MRC-5. The highest activity was observed against 
K562 cells (IC50: 5.04–6.51 µM). Selectivity indices showed that these complexes are less 
toxic than cisplatin. 3 had a similar viability kinetics on HeLa cells as cisplatin. Drug 
accumulation studies in HeLa cells showed that the total gold uptake increased much faster 
than that of cisplatin pointing out that 3 more efficiently enters the cells than cisplatin. 
Furthermore, morphological and cell cycle analysis reveal that gold(III) complexes induced 
apoptosis in time- and dose-dependent manner.  
Keywords: gold(III) complexes; R2edda-type ligands; metal uptake; apoptosis; biological 
reactivity 
1. Introduction 
Since the breakthrough in oncology of anticancer drug cisplatin, cis-[PtCl2(NH3)2], in the 
1970s, metal complexes have gained a progressively increasing interest in medicinal 
chemistry [1–5]. Although cisplatin is a widely used antitumor drug, its application is limited 
due to intrinsic and/or acquired resistance and the number of side effects, such as kidney 
damage, neurotoxicity, ototoxicity or nephrotoxicity [6–11]. Therefore, the development of 
novel metal-based complexes with reduced toxicity, improvement of clinical efficacy, and the 
development of therapeutics with a broader anticancer spectrum represent a focus of 
anticancer drug research [12–16]. Intensive research in this field, which followed the 
investigations of classical structure-activity relationship of cisplatin and its analogs, has led to 
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the discovery of thousands of active compounds, but only a small number of them have been 
considered promising for further clinical trials [7]. 
Gold(III) complexes have been applied in medicine for a long time [17–19]. The interest of 
medicinal chemistry in gold has been growing following the successful use of auranofin for 
the treatment of rheumatoid arthritis [20]. In the last decade, a number of gold(III) 
compounds with high cytotoxicity toward cancer cells have been discovered [21–24]. Having 
the square-planar geometry (d
8
 system), gold(III) complexes are isoelectronic and 
isostructural to platinum(II) complexes, and therefore, they may show a model of binding to 
DNA similar to cisplatin. The studies of gold(III) complexes and DNA interactions showed 
that binding of these compounds to nucleic acids is not as strong as that of the platinum 
drugs, suggesting a different mechanism of action of the observed biological effects [25,26], 
because their kinetic lability is higher than corresponding platinum(II) complexes. 
Additionally, it was found that cytotoxic gold(III) complexes have high reactivity toward 
different proteins [27]. Consequently, the gold-protein interactions are thought to be 
responsible for cytotoxic effects of gold-based drugs. Selenoprotein thioredoxin reductase 
(TrxR) appears to be a very specific target for these drugs [28,29]. This enzyme contains a 
cysteine-selenocysteine redox pair that is involved in the regulation of the intracellular redox 
balance [30]. It is important to note that gold(I) species, generated by gold(III) reduction in 
vivo, may represent the active metabolites of most known active gold(III) complexes [29]. 
Recently, it was demonstrated that some gold(III) complexes inhibit human 
immunodeficiency virus type-1 (HIV-1) reverse transcriptase in vitro at cytostatic 
concentrations [31–34]. 
Ligands play a crucial role in the synthesis of gold-based compounds, and their complexation 
with metal ions not only leads to the production of stable compounds, but can also, in some 
cases lead to an increase in activity and/or reduction in toxicity of these compounds [30]. 
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This may explain the cytotoxic effects of gold(III) compounds against cisplatin-resistant cell 
lines [36,37], and may provide an opportunity for gold(III) therapeutics to alleviate the side-
effects of cisplatin by providing access to combination therapies, in which the effective dose 
of cisplatin can be reduced. Bidentate N,N’ ligands, such as bis(carboxyalkylamino)ethane 
and propane ligands and their derivatives (R2edda-type ligands) [37–44], coordinate in 
κ2N,N’ manner to gold(III) ions, forming five-membered chelates [45,46]. Additionally, by 
coordinating R2edda type ligands to gold, three possible isomers can be obtained: two 
enantiomers (R,R and S,S) and one diastereoisomer (R,S) (Fig. 1).  
<<Insert Fig. 1 here>> 
In this study, synthesis, characterization, and cytotoxic activity of four novel gold(III) 
complexes with N,N’ bidentate (S,S)-R2eddl ligands [(S,S)-eddl = (S,S)-ethylendiamine-N,N’-
di-2-(4-methyl)pentanoate; R = n-Pr, n-Bu, n-Pe, i-Bu, 1–4, respectively] are presented. To 
elucidate the features determining the preferred configuration of R2edda-type ligands 
coordinated to the gold(III) complexes, density functional theory (DFT) analysis was 
performed. The stability of complex 3 in DMSO was examined, as well as the possibility of 
reduction by ascorbic acid and interactions of complex 3 with bovine serum albumin (BSA), 
using the time dependent UV/Vis and 
13
C NMR spectroscopy. All complexes were tested 
against cervix adenocarcinoma cells (HeLa), human chronic myelogenous leukemia (K562), 
human melanoma (Fem-x), and non-cancerous cells, human embryonic lung fibroblasts 
(MRC-5), with the aim of assessing their in vitro activity and selectivity. Additionally, 
cytotoxicity kinetics and gold uptake were studied. The mode of HeLa cell death induced by 
complexes 3 and 4 was studied as well, and the cell cycle distribution of HeLa, K562, and 
Fem-x cells following the treatment with these complexes were analyzed. 
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2. Experimental Section 
2.1. Materials and methods 
The n-propyl, n-butyl, n-pentyl, and isobutyl esters of (S,S)-ethylenediamine-N,N'-di-2-(4-
methyl)pentanoic acid were synthesized as described previously [47,48]. Na[AuCl4] was 
synthesized according to the standard procedure [49]. Elemental analyses were performed on 
an Elemental Vario EL III microanalyzer. A Nicolet 6700 FT–IR spectrometer and ATR 
technique were used for recording mid-infrared spectra (4000-400 cm
–1
) for all complexes. 
NMR spectra were recorded on Varian Gemini 200. Chemical shifts for 
1
H and 
13
C NMR 
spectra were referenced to internal standard TMS. Mass spectra of complexes 1–4 were 
recorded with an Orbitrap LTQ XL instrument (Thermo Scientific, Bremen, Germany) in 
CH3OH. GBC UV/Vis Cintra 6 spectrometer was used to obtain the absorption spectra of 3. 
Reagents and solvents were of commercial reagent grade quality and used without further 
purification. 
2.2. Synthesis of complexes [AuCl2{(S,S)-R2eddl}]PF6, 1–4 
Each ligand precursor [(S,S)-H2R2eddl}]Cl2 (0.126 mmol): R = n-Pr (0.056 g), or n-Bu (0.060 
g), or n-Pe (0.063 g) and i-Bu (0.060 g), respectively, was suspended in a minimum amount 
of methanol (4 mL) and LiOH·H2O (0.011 g, 0.252 mmol) was added. After 1 h of stirring 
ligand dissolved completely and Na[AuCl4]·2H2O (0.050 g, 0.126 mmol) in MeOH (4 mL) 
was introduced in the flask, followed by the addition of solid NH4PF6 (0.062 g, 0.378 mmol). 
The solution was evaporated under vacuum and the yellow product was washed with excess 
of water. The reaction was performed in the dark at room temperature. 
[AuCl2{(S,S)-n-Pr2eddl}]PF6 (1): yield 62 mg, 63%. Anal. Calcd for C20H40N2O4AuCl2PF6: 
C, 30.58; H, 5.13; N, 3.57%. Found: C, 30.98; H, 5.23; N, 3.65%. 
1
H NMR (200 MHz, 
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CDCl3): Isomers A and B: 0.90−1.10 (m, CH3CH2CH2−OOC−, C
6,7
H3, 18H), 1.73−1.95 (m, 
C
4
H2, C
5
H, 6H), 1.77 (m, CH3CH2CH2−OOC−, 4H), 3.81 (s, C
1
H2, 4H), 4.17 (m, C
2
H, 2H), 
4.26 (m, CH3CH2CH2−OOC−, 4H), 4.60 (s, NH, 2H). 
13
C NMR (50 MHz, CDCl3): Isomer 
A: 10.3 (CH3CH2CH2−OOC−), 21.5 (C
6,7
), 23,0 (CH3CH2CH2−OOC−), 24.9 (C
5
), 38.8 (C
4
), 
43.3 (C
1
), 59.1 (C
2
), 69.0 (CH3CH2CH2−OOC−), 170.1 (C
3
); Isomer B: 10.3 
(CH3CH2CH2−OOC−), 22.6 (C
6,7
), 24.5 (C
5
), 39.5 (C
4
), 52.1 (C
1
), 59.1 (C
2
), 68.5 
(CH3CH2CH2−OOC−), 169.3 (C
3
). IR (ATR, cm
−1
): νmax = 2966, 2878, 1733, 1467, 1243, 
845, 559. UV/Vis (CHCl3): λmax = 320 nm. HR ESI–MS (CH3OH), m/z: 639.2001 [M−PF6]
+
. 
[AuCl2{(S,S)-n-Bu2eddl}]PF6 (2): yield 50 mg, 49%. Anal. Calcd for C22H44N2O4AuCl2PF6: 
C, 32.48; H, 5.45; N, 3.44%. Found: C, 32.25; H, 5.76; N, 3.69%. 
1
H NMR (200 MHz, 
CDCl3): Isomers A and B: 0.90−1.10 (m, CH3CH2CH2CH2−OOC−, C
6,7
H3, 18H), 1.40 (m, 
CH3CH2CH2CH2−OOC−, 4H), 1.60−1.87 (m, C
4
H2, C
5
H, 6H), 1.68 (m, 
CH3CH2CH2CH2−OOC−, 4H), 3.30−3.70 (m, C
1
H2, 4H), 3.98 (m, C
2
H, 2H), 4.28 (t, 
CH3CH2CH2CH2−OOC−, 4H), 4.65 (s, NH, 2H). 
13
C NMR (50 MHz, CDCl3): Isomer A: 
13.5 (CH3CH2CH2CH2−OOC−), 18.9 (CH3CH2CH2CH2−OOC−), 21.5 (C
6,7
), 24.8 (C
5
), 30.2 
(CH3CH2CH2CH2−OOC−), 39.2 (C
4
), 44.2 (C
1
), 59.8 (C
2
), 67.3 (CH3CH2CH2CH2−OOC−), 
170.3 (C
3
); Isomer B: 13.5 (CH3CH2CH2CH2−OOC−), 18.9 (CH3CH2CH2CH2−OOC−), 22.4 
(C
6,7
), 25.6 (C
5
), 30.2 (CH3CH2CH2CH2−OOC−), 38.3 (C
4
), 52.5 (C
1
), 59.8 (C
2
), 66.3 
(CH3CH2CH2CH2−OOC−), 169.8 (C
3
). IR (ATR, cm
−1
): νmax= 3279, 2963, 2874, 1736, 1463, 
1246, 848, 560. UV/Vis (CHCl3): λmax = 322 nm. HR ESI–MS (CH3OH), m/z: 667.2318 
[M−PF6]
+
. 
[AuCl2{(S,S)-n-Pe2eddl}]PF6 (3): yield 55 mg, 52 %. Anal. Calcd for C24H48N2O4AuCl2PF6: 
C, 34.26; H, 5.75; N, 3.33%. Found: C, 34.46; H, 5.84; N, 3.76%. 
1
H NMR (200 MHz, 
CDCl3): Isomers A and B: 0.93 (t, CH3CH2CH2CH2CH2−OOC−, 6H), 0.99 (d, C
6,7
H3, 12H), 
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1.35 (m, CH3CH2CH2CH2CH2−OOC−, 8H), 1.71−1.90 (m, C
4
H2, C
5
H, 6H), 1.74 (m, 
CH3CH2CH2CH2CH2−OOC−, 4H), 3.40−3.90 (m ,C
1
H2, 4H), 4.10 (m, C
2
H, 2H), 4.26 (t, 
CH3(CH2)3CH2−OOC−, 4H), 4.68 (s, NH, 2H). 
13
C NMR (50 MHz, CDCl3): Isomer A: 13.8 
(CH3(CH2)4−OOC−), 21.4 (C
6,7
), 22.1 (CH3CH2(CH2)3−OOC−), 24.9 (C
5
), 27.8 
(CH3CH2(CH2)2CH2−OOC−), 38.8 (C
4
), 43.6 (C
1
), 59.5 (C
2
), 67.7 (CH3(CH2)3CH2−OOC−), 
169.7 (C
3
); Isomer B: 13.8 (CH3(CH2)4−OOC−), 22.4 (C
6,7
), 22.9 
(CH3CH2CH2CH2CH2−OOC−), 24.5 (C
5
), 38.8 (C
4
), 52.4 (C
1
), 59.5 (C
2
), 66.5 
(CH3CH2CH2CH2CH2−OOC−), 169.2 (C
3
). IR (ATR, cm
−1
): νmax = 2960, 2934, 2871, 1735, 
1466, 1248, 847, 559. UV/Vis (CHCl3): λmax = 318 nm. HR ESI–MS (CH3OH), m/z: 
695.26239 [M−PF6]
+
. 
[AuCl2{(S,S)-i-Bu2eddl}]PF6 (4): yield 59 mg, 58 %. Anal. Calcd for C22H44N2O4AuCl2PF6: 
C, 32.48; H, 5.45; N, 3.44%. Found: C, 32.31; H, 5.44; N, 3.53%. 
1
H NMR (200 MHz, 
CDCl3): Isomers A and B: 0.88−1.02 (m, (CH3)2CHCH2−OOC−, C
6,7
H3, 24H), 1.79−2.10 
(m, (CH3)2CHCH2−OOC−, C
4
H2, C
5
H, 8H), 3.70−3.90 (m, C1H2,4H), 4.10 (m, C
2
H, 2H), 
4.19 (m, (CH3)2CHCH2−OOC−, 4H). 
13
C NMR (50 MHz, CDCl3): Isomer A: 18.9 
(CH3)2CHCH2−OOC−), 21.4 (C
6,7
), 24.9 (C
5
), 27.4 ((CH3)2CHCH2−OOC−), 38.7 (C
4
), 43.7 
(C
1
), 59.8 (C
2
), 73.8 (CH3)2CHCH2−OOC−), 169.7 (C
3
); Isomer B: 18.9 
(CH3)2CHCH2−OOC−), 22.9 (C
6,7
), 24.9 (C
5
), 27.4 ((CH3)2CHCH2−OOC−), 39.4 (C
4
), 52.6 
(C
1
), 59.8 (C
2
), 73.3 (CH3)2CHCH2−OOC−),  169.4 (C
3
). IR (ATR, cm
−1
): νmax = 3189, 2965, 
2877, 1729, 1467, 1244, 846, 559. UV/Vis (CHCl3): λmax = 320 nm. HR ESI–MS (CH3OH), 
m/z: 667.2407 [M−PF6]
+
. 
2.3. Computational details 
Gaussian 09 package was used to perform geometry optimizations [50].
 
B3LYP functional 
was used for structure optimizations [51] and the Stuttgart/Dresden (SDD) basis set was 
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employed for all atoms in the calculations [52,53]. Optimizations of all systems were done 
without symmetry restrictions. Resulting geometries were characterized as equilibrium 
structures by analysis of force constants of normal vibrations.  
2.4. Stability of complex 3 in DMSO  
Stability study was performed in DMSO and CHCl3 for complex 3 by UV/Vis spectrometry. 
Fresh solution of 3 (c = 1 × 10
–3
 M) in DMSO or CHCl3 was recorded immediately and after 
24 h.
 
2.5. Reduction of complex 3 with ascorbic acid 
Complex 3 (20 mg, 0.024 mmol) was dissolved in deuterated acetone (0.4 mL) in an NMR 
tube. Afterwards, 50 mg of ascorbic acid (0.280 mmol, excess, molar ratio 1:12) was added. 
13
C NMR spectra were recorded before and after the addition (immediately, at 2, 24, and 48 
h) of ascorbic acid [46].
 
2.6. Interaction of complex 3 with BSA 
Stock solution of 3 (c = 3.33 × 10
–3
 M) was prepared in methanol. The investigated samples 
were obtained using same concentration of BSA (4 × 10
–6
 M) in PBS (phosphate-buffered 
saline, pH 7.4) and different concentrations of the gold(III) complex 3 (1 × 10
–4
, 2 × 10
–4
, 3 × 
10
–4
, 4 × 10
–4 
and 5 × 10
–4
 M). Explicitly, different aliquots of the stock solution of 3 (0.3, 
0.6, 0.9, 1.2, 1.5 mL) were added to 5 mL of a 8 × 10
–6
 M BSA solution in PBS and the 
volumetric flask was filled with PBS up to 10 mL. These solutions were prepared freshly and 
UV/Vis spectra were recorded immediately, and after 2, 24, and 48 h [46]. 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
9 
 
2.7. Preparation of drug solutions  
The solutions of the investigated gold(III) complexes were prepared in DMSO (Sigma-
Aldrich, St. Louis, MO, USA) at the concentrations of 20 mM, and diluted by nutrient 
medium to various working concentrations. Nutrient medium was RPMI-1640 (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Biochrom 
AG, Berlin, Germany) and penicillin/streptomycin (Sigma-Aldrich St. Louis, MO, USA). 
Media were supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 1% 
penicillin-streptomycin (Sigma). 
2.8. Cell lines 
Cervix adenocarcinoma cell line (HeLa), human melanoma (Fem-x), human chronic 
myelogenous leukemia cells (K562), and a non-cancerous cell line, MRC-5 (human 
embryonic lung fibroblast) were grown in complete RPMI-1640 medium (Sigma-Aldrich, St. 
Louis, MO, USA). 
2.9. Determination of cell survival 
Target cells HeLa (2000 cells/well), Fem-x (5000 cells/well), K562 (5000 cells/well), and 
non-cancerous MRC-5 (5000 cells/well) were seeded into the wells of a 96-well flat-
bottomed microtitre plate. Twenty-four hours later, after the cell adhesion, different 
concentrations of investigated compounds were added to the wells, except for the controls, 
where only the complete medium was added. The final concentration range used in the 
experiments was 1–50 µM (3.13, 6.25, 12.5, 25, and 50 µM). Cisplatin was used as the 
positive control, and the final concentrations used here were 2.08, 4.17, 8.33, 16.67, and 33.3 
µM. The final concentration of DMSO never exceeded 0.5%, which is a non-toxic 
concentration for the cells. For K562 cells, the compounds were applied 2 h after cell 
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seeding. Culture medium with corresponding concentrations of investigated compounds, but 
without cells, was used as blank. The cultures were incubated for 72 h, and the effects of the 
investigated compounds on cancer cell survival were determined using the microculture 
tetrazolium test (MTT), according to Mosmann [54] with modification by Ohno and Abe 
[55], 72 h after the addition of the investigated compounds. Briefly, 20 L of MTT solution 
(5 mg/mL of phosphate-buffered saline, PBS) was added to each well. Samples were 
incubated for additional 4 h at 37°C in a humidified atmosphere of 5% CO2 (v/v). Afterward, 
100 mL of 100 g/L sodium dodecyl sulfate (SDS) were added in order to extract the insoluble 
formazan, which represents the product of the conversion of the MTT dye by viable cells. 
The number of viable cells in each well is proportional to the intensity of the absorbance (A) 
of light, which was measured in an enzyme-linked immunosorbent assay (ELISA) plate 
reader at 570 nm, 24 h later. To determine cell survival (%), the A of a sample with cells 
grown in the presence of various concentrations of the investigated compounds was divided 
by the control optical density (the A of control cells grown only in nutrient medium) and 
multiplied by 100. The A of the blank was always subtracted from the A of the corresponding 
sample incubated with the target cells. IC50 is defined as the concentration of an agent 
inhibiting cell survival by 50% compared with the vehicle-treated control. All experiments 
were performed in technical and biological triplicates.  
2.10. Time dependent cytotoxicity studies  
Activity of the gold(III) complex 3 along with cisplatin on HeLa was measured for 0, 4, 8, 
24, 48 and 72 h at equitoxic concentrations of each compound, respectively. The cytotoxic 
activity was performed according to the MTT microculture colorimetric assay protocol, 
except that after each time point the cells in 96-well plates were washed with PBS and grown 
in drug–free medium up to 96 h.  
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2.11. Gold drug accumulation in cells 
The gold uptake studies were performed using HeLa cells. The cells were seeded in 25-cm
2
 
flasks and allowed to grow. After 24 h, the exponentially growing cells were treated with 
equtoxic concentrations of complex 3 and cisplatin for 24, 48 and 72 h, and afterwards 
trypsinized and collected by centrifugation at 1000 rpm for 10 min. The cells were washed 
with ice-cold PBS. The digestion of the samples for ICP-MS measurements was performed 
on an Advanced Microwave Digestion System (ETHOS 1, Milestone, Italy) using HPR-
1000/10S high pressure segmented rotor which were equipped with QS-50 Quartz inserts:  
sample with of 5 mL HNO3 (65%, Suprapure®, Merck, Germany). Gold concentrations were 
measured using inductively coupled plasma mass spectrometry (ICP-MS) on Thermo 
Scientific iCAP Qc ICP-MS (Thermo Scientific, Bremen, Germany) spectrometer with 
operational software Qtegra. The instrument was optimized for optimum performance in He 
KED (kinetic energy discrimination) mode, using the supplied autotune protocols. The ICP-
MS instrument was tuned using a solution TUNE B iCAP Q (1 μg/L of each: Ba, Bi, Ce, Co, 
In, Li, U) provided by the manufacturer Thermo Scientific, Germany. External standards for 
the instrument calibration were prepared on the basis of a gold plasma standard solution 
(Specpure, Au 1000 µg/mL certified reference solution ICP Standard purchased from Alfa 
Aesar GmbH & Co KG, Germany). For cellular uptake experiments, the limit of quantitation 
(LOQ) for gold was determined to be 86 ng/L. The measurement was performed on isotope 
197
Au [56]. 
2.12. Cell cycle analysis 
HeLa, Fem-x, K562 cells were seeded in six-well plates (3 × 10
5
 cells/well), and, except for 
the control cells, treated with the investigated compounds after 24 h of incubation. Afterward, 
they were incubated at 37°C for the additional 24 or 48 h. Concentrations used corresponded 
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to the previously determined IC50 and 2×IC50 values. Following the incubation, the cells were 
collected by trypsinization, fixed in ice-cold 70% ethanol for 1 h on ice, and incubated at 
−20°C for at least one week. Afterward, the cells were washed in PBS and pellets obtained by 
centrifugation were treated with RNAse (100 μg/mL) at 37°C for 30 min and incubated with 
propidium iodide (PI) (40 μg/mL) for at least 30 min. DNA content and cell-cycle 
distribution were analyzed using Becton Dickinson FACSCalibur flow cytometer. Flow 
cytometry analysis was performed using CellQuestR (Becton Dickinson, San Jose, CA, USA) 
software with a minimum of 10,000 cells per sample [57].
 
2.13. Morphological analysis (AO/EB double staining) 
The investigated compound-induced cell death was determined using acridine orange (AO) 
and ethidium bromide (EB) double staining, according to the standard procedures and 
examined under a fluorescence microscope [58]. O/EB double staining assay can be used 
for detection of apoptosis, autophagy and necrosis in the cells [59]. AO can cross the cell 
membrane and viable and early apoptotic cells can be identified. Chromatin condensation, 
seen as dense green areas, or membrane blebbing, both appearing in apoptosis, is easily 
proven by AO staining. Moreover, orange to red autophagosomes might be detected by AO 
pointing out autophagic process in the cells. EB can not cross intact membrane, thus only 
necrotic cells can be identified by EO (cytoplasm stained red). HeLa cells were seeded 
overnight on coverslips (100,000 cells/coverslip) in 2 mL of complete medium. The 
following day, cells were treated with IC50 of the investigated compounds for 24 h. After this 
period, coverslips with target cells were stained with acridine orange/ethidium bromide 
mixture (3 μg/mL AO and 10 μg/mL EB in PBS), and visualized under a fluorescence 
microscope (Fluorescence microscope-PALM MicroBeam systems, Carl Zeiss, Oberkochen, 
Germany). 
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3. Results and Discussion 
3.1. Synthesis and characterization 
In the reaction of Na[AuCl4]∙2H2O and an equimolar amount of corresponding ligand 
(Scheme 1), previously deprotonated with LiOH∙H2O, upon precipitation in the presence of 
PF6
–
 ions the desired complexes 1–4 were obtained in moderate to good yields. The prepared 
complexes were shown to be soluble in methanol, ethanol, acetone, dichloromethane, 
chloroform, dimethyl sulfoxide, and acetonitrile. HR ESI-MS were recorded in positive ion 
mode, and in all cases, the [M−PF6]
+
 mass peak was detectable. Furthermore, stoichiometric 
formulae of synthesized complexes were in agreement with elemental analysis. 
<<Insert Scheme 1 here>> 
IR spectra of synthesized complexes (Table 1) showed strong ν(C=O) stretching bands from 
1729–1736 cm–1 [60], which was similar to the corresponding ligand precursors [47,48], 
indicating that coordination of carbonyl oxygen atoms to the gold(III) center has not 
occurred. Asymmetric ν(–CH3/–CH2/–CH) stretching vibrations of moderate intensities were 
recorded in the range of 2871–2966 cm–1. Coordination through the nitrogen atom can be 
concluded based on changes in values of asymmetric C–N vibrations from 798–803 (ligand 
precursors) to 845–848 cm–1 (1–4) [60]. 
<<Insert Table 1 here>> 
The data obtained using UV/Vis spectroscopy showed absorption around 320 nm, which can 
be assigned to Cl→Au charge transfer, by analogy to auric acid absorption spectra [61]. 
Similar electronic transitions are observed in analogous gold(III) complexes [45,46]. 
According to crystal field theory of d
8
 complexes, the lowest unoccupied molecular orbital 
(LUMO) is , and therefore, the ligand to metal charge transfer could be due to pσ → 
 transition [62]. 
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Selected NMR data are presented in Table 2. In 
1
H NMR spectra the chemical shifts of CH2 
protons of the ethylenediamine bridge show coordination induced shifts (up to 0.5 ppm) for 
all complexes, giving a clear indication of nitrogen coordination. Resonances of protons from 
ester alkyl moieties of 1–4 were located between 0.88 and 2.10 ppm. The hydrogen atoms 
belonging to the secondary amino groups of complexes appeared in the 
1
H NMR spectra at 
approximately 4.65 ppm. The protons between carboxylic group and nitrogen atom were 
found in the range from 3.98–4.10 ppm. Finally, CH2O can be seen around 4.20 ppm, as 
expected [47,48]. 
<<Insert Table 2 here>> 
In 
13
C NMR spectra, chemical shifts arising from ester carbon atoms were found at the 
expected positions for this class of compounds [47,48]. Thus, resonances at around 170 ppm 
(C
3
) clearly demonstrates that oxygen atoms do not participate in coordination. The carbon 
atom chemical shifts from ethylenediamine moiety (C
1
) in the complexes are shifted 
downfield relative to those of the ligand precursors [47,48]. Two sets of chemical shifts can 
be observed in the 
13
C NMR spectra, the most pronounced ones being those of carbon atoms 
from the ethylenediamine bridge and carboxyl groups, which indicates the possible existence 
of isomers (Table 2). Complete characterization of complex 3, as an example, can be seen in 
supplementary section (Fig. S1–S4). 
 
3.2. Quantum chemical calculations 
DFT calculations were conducted for the isomers arising from κ2N,N’ coordination of (S,S)-
R2eddl (R = n-Pr, n-Bu, n-Pe, i-Bu) to AuCl2 fragment (denoted as 1c–4c). Equilibrium 
structures are shown for 1c as an example in Fig. 2. All structures were fully optimized 
without any symmetry constraints. The calculated results for complexes 1c–4c showed that 
the (R,R)-N,N’ diastereoisomer is energetically the most stable one. Namely, the energy 
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difference between (R,R)-1c–4c and (R,S) ≡ (S,R)-1c–4c diastereoisomers is around 3.3 
kcal/mol. The energy of the third isomer, (S,S)-1c–4c, is around 6.0 kcal/mol higher than the 
energy of (R,R)-1c–4c. NMR spectra show two sets of signals and DFT calculations point out 
that those two isomers might be (R,R) and (R,S) configured.  
<<Insert Fig. 2 here>> 
3.3. Stability and reactivity 
The stability of anticancer drugs is one of the most important factors for understanding the 
cytotoxic activity of these complexes in the organism. Therefore, complex 3 was selected and 
its stability in DMSO and CHCl3 was investigated. Moreover, the reactivity of 3 with BSA 
was investigated by UV/Vis spectroscopy and its reactivity with ascorbic acid has been 
examined with 
13
C NMR spectroscopy [63–65].  
<<Insert Fig. 3 here>> 
UV/Vis spectra of 3 in DMSO correspond to the spectra recorded in CHCl3, and no time-
dependent appearance (24 h) of the new absorption maximum was observed (Fig. 3). Many 
studies have shown that reducing substances, such as ascorbic acid, and thiol-containing 
species, for example metallothioneins and glutathione, may be regarded as the activators of 
gold(III) prodrugs [66,67]. In order to investigate the possibility that [AuCl2{(S,S)-(n-
Pe)2eddl}]
+
, (3–PF6) is reduced in cells with biologically relevant reductant, time-dependent 
13
C NMR spectroscopy was performed for the reaction of complex 3 with ascorbic acid. As 
presented in Fig. 4, ascorbic acid reduces the complex immediately, indicating that this 
reaction in the cells is probable as well. 
<<Insert Fig. 4 here>> 
Interaction of complex 3 with BSA, which was selected both as the most abundant plasma 
protein and as a general model for globular proteins, has been investigated. Serum albumins 
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have many physiological functions. They contribute to colloid osmotic blood pressure and are 
chiefly responsible for the maintenance of blood pH [68]. 
Presumably, metal-BSA adducts formed due to the coordination of surface histidines and/or 
cysteines to metal ions [69,70]. Moreover, S-donors, such as L-methionine and the L-cysteine 
34 residues of albumin are usual targets for gold compounds [71]. Interactions between 
freshly prepared solutions of complex 3 and BSA were examined at room temperature by 
UV/Vis spectrometry over time. In Fig. 5, spectra for different time points, using several 
concentrations of 3 (1 × 10
–4
 – 5 × 10–4 M), and same concentration of BSA (4 × 10–6 M) are 
presented. Espósito et al. recently reported [71], also in agreement with our recent study [46], 
that there is a high possibility that [AuCl2{(S,S)-(n-Pe)2eddl}]
+
 may be reduced with L-
cysteine, leading to gold(I) complex as deduced by the disappearance of the LMCT gold(III) 
absorption (ca. 320 nm) observed 2 h after the reaction was initiated (Fig. 5). After 24 and 48 
h, UV/Vis spectra indicate that gold(I) species might disproportionate to corresponding 
gold(III) complex and elemental gold [46,72]. Complex 3 seems to react in similar manner as 
[Au(en)Cl2]
+
, which is in agreement with literature data. Additionally, a new absorption band 
appears at 540 nm, thus implying the formation of colloidal gold [46,73]. 
<<Insert Fig. 5 here>> 
3.4. Cytotoxic activity  
In Fig. 6, graphs showing the survival of HeLa, Fem-x, K562, and non-cancerous MRC-5 
cells, in the presence of different concentrations of gold(III) complexes 1–4, are presented. 
These results were obtained by MTT test, after 72 h of incubation with investigated 
compounds. Cisplatin was used as a positive control. The obtained results are presented in 
Table 3. The investigated complexes showed the highest activity against K562 cells, with 
IC50 ranging from 5.0 to 6.7 µM, and these IC50 values are similar to that of cisplatin.  
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<<Insert Fig. 6 here>> 
<<Insert Table 3 here>> 
However, the cytotoxic activity of these complexes against HeLa and Fem-x cells was 
slightly lower, with IC50 ranging from 8.1 to 13.6 µM. Experiments with the normal human 
cell line showed that these complexes are less toxic than cisplatin. Nevertheless, there was no 
considerable selectivity observed in the activity of these complexes, except against leukaemia 
K562 cells. Selectivity indices are given in Table 4. These results indicate that the 
investigated complexes may offer the potential for further development of novel antileukemic 
treatments. 
<<Insert Table 4 here>> 
Even though the investigated compounds demonstrated the highest cytotoxicity toward K562 
cells, HeLa cells were selected for further studies for several simple reasons. Namely, K562 
cells are non-adherent cells, unlike all other cell lines used in this study. Therefore, drug-
sensitivity of these cells is usually the highest, not depending on the compound being tested, 
meaning that further experiments using these cells most likely cannot provide us with the 
information about specific activity of the tested compounds. Additionally, non-adherent cells 
are easier to use in kinetic and drug uptake studies. Since the majority of cancers we are 
studying are solid tumors, with cells that adhere to the substrates, we have selected HeLa 
cells as a stable cell line which is used in a variety of experiments in many laboratories, 
facilitating the comparisons between the results obtained in our study and those obtained by 
other groups. 
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3.5. Kinetic studies 
Kinetic profile of cytotoxic activity was investigated for the complexes 1–4 and cisplatin, in 
HeLa cell line, as percentage of cell survival in function of time [40]. As shown in Fig. 7 
representative complex 3 acts very similar to the reference compound, cisplatin. Most of the 
cancer cells stay alive in the first 8 h, but the majority is dead by the 24 h. Cell survival for 
both tested compounds stays around 6–7% in the next period (24–72 h). Since cisplatin is 
regularly used worldwide as prescribed chemotherapy in the treatment of several cancer 
types, for complex 3 showing same behavior, by means of kinetic profile, could be 
considered as a highly desirable feature. 
 
3.6. Drug uptake 
Intracellular gold and platinum uptake in HeLa cells was determined using ICP-MS 
[40,74,75]. Treatment of cells with 3 and cisplatin resulted in significantly different metal 
uptake (Fig.7). After 24 h, platinum accumulation was 40 ppm, while gold was found to exert 
ca. 1400 ppm, which is 34 fold higher. At the 48 h time point, uptake of platinum was 91 
ppm while for gold was found 1724 ppm, thus 19 fold higher. At the end of the experiment, 
after 72 h, 190 ppm of platinum and 3680 ppm of gold, somewhat more than 19 times higher, 
entered HeLa cells. In comparison to cisplatin, complex 3 shows much better cellular uptake, 
and furthermore the drug accumulation is the most different in the first 24 h, even 34 fold 
higher than for the clinically used anticancer drug, showing better absorption in cells. 
<<Insert Fig. 7 here>> 
Kinetic study and drug uptake for cisplatin and complex 3 correlate well. Thus, as higher as 
the concentration of compounds is present in the cells, viability decreases. Treatment of HeLa 
cells with equtoxic drug concentrations declines in a similar manner cell viability within 24 h. 
On the other hand, IC50 values of cisplatin and 3 do not have a direct correlation with the 
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amount of uptaken metal. However, cisplatin remains unused in extracellular milieu in at 
least 19 times higher concentration than 3. Additionally, it should be pointed out that 
complex 3 enters much faster than cisplatin in HeLa cells.  
 
3.7. Cell cycle effects 
In order to examine cytotoxic mechanisms of complexes 3 and 4, the effects of these 
compounds on the distribution of cancer cells (HeLa, Fem-x, and K562) in the cell cycle 
phases was analysed. Dose-dependent changes in the distribution of HeLa cells was observed. 
Moreover, incubation with the compounds for 24 h led to an increase in the percentage of 
cells in sub-G1 phase only when cells were treated with 2×IC50 concentration of the 
complexes. Additionally, complex 3 exerted better effects after 48 h, leading to a 
considerable increase in sub-G1 phase in cells treated with 2×IC50 of the compounds, which 
was coupled with a decrease in the percentage of cells in S and G2/M phases (Fig. 8). Similar 
effects of complex 4 were observed toward Fem-x cells, with a considerable increase in the 
percentages of cells in sub-G1 phase, which was dose-dependent, but the treatment with 
complex 3 did not lead to any observable changes (Fig. 8). Furthermore, in the case of K562 
cells the incubation with the complexes 3 and 4 led to a dose- and time-dependent increase in 
the number of cells in sub-G1 phase (Fig. 8). 
<<Insert Fig. 8 here>> 
Results indicate that the investigated complexes lead to the induction of presumably 
apoptosis in these cells. The action of investigated gold(III) complexes on cell lines is time- 
and dose-dependent. Additionally, complex 3 was not able to induce the increase in the 
number of Fem-x cells in the sub-G1 phase, suggesting that this complex probably has a 
different mode of action.  
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3.8. Morphological study 
Fig. 9 shows the microphotographs of HeLa cells, stained with AO/EB, following the 
treatment with complexes 3 and 4. Morphological changes of the treated cells can be easily 
identified along with the condensation of the nucleus. These changes are especially 
prominent in the cells treated with the IC50 and 2×IC50 of complex 4, where nuclear shrinkage 
and chromatin condensation are considerable, in comparison with the control cells. In the 
cells treated with 2×IC50 of 4, even the initial stages of secondary necrosis can be observed, 
this is usual for apoptotic cells in culture, at the end point they must necrotize. Thus in 
accordance to the cell cycle analysis, the results of fluorescent staining of HeLa cells 
demonstrate that the investigated complexes induce apoptosis, a controlled cell death. 
<<Insert Fig. 9 here>> 
 
4. Conclusions 
The results presented here describe the synthesis of four novel gold(III) complexes, 1–4, with 
O,O’-dialkyl-(S,S)-ethylenediamine-N,N’-di-2-(4-methyl)pentanoate ligands. The compounds 
were characterized by elemental analysis, UV/Vis, IR and NMR spectroscopy, and mass 
spectrometry. The UV/Vis and 
1
H and 
13
C NMR spectral data suggest N,N’ bidentate 
coordination of ligands to central metal ion. NMR spectra showed the presence of two 
isomers, and DFT calculations indicated that (R,R)-N,N’ diastereoisomer is energetically the 
most stable one. Complex 3 was stable in DMSO during 24 h of incubation, but was 
immediately reduced in the reaction with ascorbic acid, indicating a high possibility of the 
same outcome in living cells. The interactions of complex 3 with BSA, examined by UV/Vis 
spectroscopy can be clearly observed. The possible reduction of gold(III) ion to gold(I) 
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species and disproportion to colloidal gold due to the interactions with biomolecules is of 
interest in the field of gold nanoparticles with medicinal applications [76].  
The cytotoxic in vitro activity of all synthesized compounds against human tumor cell lines, 
HeLa, K562, and Fem-x, as well as against non-cancerous human embryonic lung fibroblast 
cell line, MRC-5, was demonstrated. The complexes showed the highest activity against 
K562 cells (IC50: 5.0–6.7 µM), comparable to that of cisplatin. Additionally, the complexes 
were shown to be less toxic than cisplatin toward normal human cells. Kinetic studies in 
HeLa cells revealed that complex 3 acts very similarly in comparison to cisplatin, a regularly 
used anticancer drug worldwide. Metal accumulation study in HeLa cells showed that the 
gold uptake increased in a time-dependent manner, and that complex 3 accumulated much 
more efficiently (at least 19 times), than cisplatin at equitoxic concentrations. Cell cycle 
distribution analysis confirmed that the investigated complexes 3 and 4 have pro-apoptotic 
effects, as demonstrated by the increase in the percent of HeLa and K562 cells in sub-G1 
phase. In contrast to this, since the corresponding increase in the number of cells in this phase 
was not observed after the treatment of Fem-x cells, this indicates that complexes 3 and 4 
may have pleiotropic effects, and that their effects depend on the type of cancer cell. Thus, 
these compounds have multiple, diverse, effects, which may depend on the type of cancer 
cell. Many therapeutics currently in use in clinic have pleiotropic effects [77], and therefore, 
further investigations should determine the main cancer types against which these compounds 
are the most effective. Morphological examinations of HeLa cells upon treatment are in 
accordance to cell cycle analysis results, confirming that 3 and 4 induce apoptosis, a 
controlled cell death. All of these findings are leading to a conclusion that 3 and 4 may be 
considered as good candidates for further investigations. 
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Abbreviations 
 
AA: Ascorbic acid 
AO: Acridine orange 
BSA: Bovine serum albumin 
EB: Ethidium bromide 
DFT: Density functional theory 
DMSO: dimethyl sulfoxide 
Fem-x: Human melanoma cell line 
HeLa: Human adenocarcinoma cell line 
HR ESI-MS: High-resolution electrospray ionization mass spectrometry 
ICP-MS: Inductively coupled plasma mass spectrometry 
IR: Infrared spectroscopy 
K562: Human myelogenous leukemia cell line 
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MRC-5: Non-cancerous cell line human embryonic lung fibroblast 
NMR: Nuclear magnetic resonance spectroscopy 
PBS: Phosphate-buffered saline 
R2edda-type ligand: O,O’-dialkyl-ethylenediamine-N,N’-diacetate ester derivatives 
R2eddl: O,O’-dialkyl-(S,S)-ethylenediamine-N,N’-di-2-(4-methyl)pentanoate ester 
R: Alkyl 
n-Pr: n-propyl  
n-Bu: n-butyl 
n-Pe: n-pentyl 
i-Bu: i-butyl 
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FIGURE/SCHEME CAPTIONS 
 
Fig. 1. Possible isomers of gold(III) complexes with R2edda-type ligands. 
Fig. 2. Calculated structures of 1c, as an example. H atoms, except those bonded to 
chiral atoms, have been omitted for clarity. 
Fig. 3. Stability of complex 3. 
Fig. 4. Reduction of 3 with ascorbic acid followed by 
13
C NMR spectroscopy over 
time. 
Fig. 5. Interaction of 3 with BSA followed by UV/Vis spectrometry over time. 
Concentrations of 3: 1 × 10
–3
 M; a–e: 1 × 10–4 – 5 × 10–4 M, respectively; 
BSA: 4 × 10
–6 
M. 
Fig. 6. The survival of HeLa, Fem-x, K562, and MRC-5 cells incubated for 72 h with 
different concentrations of investigated complexes (MTT assay, 72 h) : 1 
(diamonds), 2 (squares), 3 (triangles), 4 (crosses). 
Fig. 7. Kinetics of growth inhibition and metal uptake in HeLa cells treated with 
equitoxic concentrations of representative gold(III) complex, 3 (12.06 µM), 
and cisplatin (2.37 µM). 
Fig. 8. Cell cycle distribution analysis of HeLa, Fem-x, and K562 cells, after 24 and 
48 h of incubation with IC50 and 2×IC50 of complexes 3 and 4. 
Fig. 9. Microphotographs of AO/EB double stained HeLa cells. 
 
Scheme 1. Synthesis of complexes 1–4. 
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Fig. 1. Possible isomers of gold(III) complexes with R2edda-type ligands. 
 
Fig. 2. Calculated structures of 1c, as an example. H atoms, except those bonded to chiral 
atoms, have been omitted for clarity. 
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Fig. 3. Stability of complex 3. 
 
Fig. 4. Reduction of 3 with ascorbic acid followed by 
13
C NMR spectroscopy over time. 
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Fig. 5. Interaction of 3 with BSA followed by UV/Vis spectrometry over time. 
Concentrations of 3: 1 × 10
–3
 M; a–e: 1 × 10–4 – 5 × 10–4 M, respectively; BSA: 4 × 10–6 M. 
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Fig. 6. The survival of HeLa, Fem-x, K562, and MRC-5 cells incubated for 72 h with 
different concentrations of investigated complexes (MTT assay, 72 h): 1 (diamonds), 2 
(squares), 3 (triangles), 4 (crosses). 
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Fig. 7. Kinetics of growth inhibition and metal uptake in HeLa cells treated with equitoxic 
concentrations of representative gold(III) complex, 3 (12.06 µM), and cisplatin (2.37 µM). 
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Fig. 8. Cell cycle distribution analysis of HeLa, Fem-x, and K562 cells, after 24 and 48 h of 
incubation with IC50 and 2×IC50 of complexes 3 and 4. 
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Fig. 9. Microphotographs of AO/EB double stained HeLa cells. 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
38 
 
 
Scheme 1. Synthesis of complexes 1–4. 
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TABLE CAPTIONS 
 
Table 1. Selected IR data (in cm
–1
) for complexes 1–4. 
Table 2. Selected 
1
H and 
13
C NMR data (in ppm) for complexes, 1–4. 
Table 3. Concentrations of complexes 1–4 that were able to induce 50% decrease in cell 
survival (IC50, µM), after 72 h of incubation (mean ± SD) 
Table 4. Selectivity indices 
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Table 1. Selected IR data (in cm
–1
) for complexes 1–4. 
Complexes ν(–CH3/−CH2/–CH) ν(C=O) ν(C−O) ν(C−N) 
1 2966; 2878 1733 1243 845 
2 2963; 2874 1736 1246 848 
3 2934; 2871 1735 1248 847 
4 2965; 2877 1729 1244 846 
 
Table 2. Selected 
1
H and 
13
C NMR data (in ppm) for complexes, 1–4. 
Complexes Isomers 
 1H   
13
C   
C
1
H2 CH2O C
2
H C
1
 C
2
 C
3
OO CH2O 
1 
A 
B 
3.81 4.26 4.17 
43.3 
52.1 
59.1 
170.1 
169.3 
69.0 
68.5 
2 
A 
B 
3.30-3.70 4.28 3.98 
44.2 
52.5  
59.8 
170.3 
169.8 
67.3 
66.3 
3 
A 
B 
3.40-3.90 4.26 4.10 
43.6 
52.4 
59.5 
169.7 
169.2 
67.7 
66.5 
4 
A 
B 
3.70-3.90 4.19 4.10 
43.7 
52.6 
59.8 
169.7 
169.4 
73.8 
73.3 
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Table 3. Concentrations of complexes 1–4 that were able to induce 50% decrease in cell 
survival (IC50, µM), after 72 h of incubation (mean ± SD) 
Complexes 
IC50 [μM] 
HeLa Fem-x K562 MRC-5 
1 13.61 ± 1.79 13.10 ± 0.31 6.51 ± 1.52 18.58 ± 0.47 
2 12.47 ± 2.22 9.26 ± 4.09 5.04 ± 2.49 26.11 ± 4.06 
3 12.06 ± 1.53 8.08 ± 1.94 6.74 ± 0.69 19.08 ± 2.74 
4 10.65 ± 0.83 13.33 ± 0.81 6.37 ± 1.36 19.44 ± 1.99 
cisplatin 2.37 ± 0.41 4.71 ± 0.35 5.82 ± 0.17 13.98 ± 0.52 
 
 
Table 4. Selectivity indices 
Complexes 
IC50(MRC-5)/IC50(cell line) 
HeLa Fem-x K562 
1 1.37 ± 0.18 1.42 ± 0.05 2.85 ± 0.67 
2 2.09 ± 0.49 1.93 ± 1.32 5.18 ± 2.68 
3 1.58 ± 0.30 2.36 ± 0.66 2.83 ± 0.50 
4 1.83 ± 0.23 1.46 ± 0.17 3.05 ± 0.72 
cisplatin 5.18 ± 0.81 2.97 ± 0.25 2.40 ± 0.11 
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Graphical abstract 
Synthesis, characterization, stability, interactions with bovine serum albumin and ascorbic 
acid, in vitro anticancer activity, cell cycle and mode of cell death, as well as kinetics study 
and drug uptake of novel gold(III) complexes of general formula [AuCl2{(S,S)-R2eddl}]PF6, 
(R2eddl = O,O’-dialkyl-(S,S)-ethylenediamine-N,N’-di-2-(4-methyl)pentanoate; R = n-Pr, n-
Bu, n-Pe, i-Bu) are presented.  
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Highlights 
 
 Four new gold(III) complexes with N,N’-ethylenediamine bidentate esters are 
prepared. 
 Highest activity is against K562 cells, indicating novel antileukemic treatments. 
 The most active Au(III) complex accumulated in cells more efficiently than cisplatin.  
 The mode of cell death induced by these complexes is apoptosis. 
 The most active Au(III) complex interacts with bovine serum albumin (BSA). 
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